3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 1/2
2
Phase 1
2
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Thoracic
1
Head & Neck
1
Gastrointestinal
1
Breast
1
Conditions
Prostatic Neoplasms
383
Carcinoma, Renal Cell
210
Urinary Bladder Neoplasms
117
Carcinoma, Non-Small-Cell Lung
99
Melanoma
78
Kidney Neoplasms
74
Carcinoma, Transitional Cell
73
Neoplasm Metastasis
72
Ovarian Neoplasms
71
Breast Neoplasms
69
Neoplasms
64
Colorectal Neoplasms
59
Squamous Cell Carcinoma of Head and Neck
50
Stomach Neoplasms
49
Uterine Cervical Neoplasms
44
Pancreatic Neoplasms
44
Triple Negative Breast Neoplasms
39
Lung Neoplasms
35
Esophageal Neoplasms
32
Non-Muscle Invasive Bladder Neoplasms
31
Endometrial Neoplasms
30
Carcinoma, Hepatocellular
29
Sarcoma
28
Small Cell Lung Carcinoma
25
Head and Neck Neoplasms
25
Colonic Neoplasms
19
Wilms Tumor
15
Metastatic Castration-resistant Prostate Cancer
14
Glioblastoma
14
Carcinoma, Merkel Cell
14
Interventions
derazantinib
1
atezolizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 1/2
×
Acrocephalosyndactylia
×
Genitourinary
×
Clear all
NCT07292168
2026-01-21
TAGNOT
Kidney Cancer Research Bureau
Phase 1/2
Recruiting
58 enrolled
NCT04045613
2023-10-13
FIDES-02
Basilea Pharmaceutica
Phase 1/2
Completed
95 enrolled
25 charts